Skip to main content

Table 4 Induction treatment regimes

From: Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia

Regime N (%)
Daunorubicine and Cytarabine (n = 116) or Daunorubicine, cytarabine and mitoxantrone (n = 2) 118 (62.4)
Idarubicine and Cytarabine (n = 26) or Idarubicine, Cytarabine and Etoposide (n = 3) 29 (15.3)
Idarubicine, Cytarabine and Cladribine 20 (10.6)
Mitoxantrone, cytarabine and Etoposide (n = 7) or Mitoxantrone and Cytarabine (n = 2) 9 (4.8)
Daunorubicine, Cytarabine and 6-Thioguanine 8 (4.2)
Other/unknown1 5 (2.6)
  1. 1Including 2 in clinical trial of combination therapy with Tipifarnib, and 1 with Fludarabine, Cytarabine and G-CSF. 2 patients with unknown treatment but known curative intent.